Literature DB >> 10611843

Serological evidence of Chlamydia pneumoniae lipopolysaccharide antibodies in atherosclerosis of various vascular regions.

I Körner1, R Blatz, I Wittig, D Pfeiffer, C Rühlmann.   

Abstract

BACKGROUND: The role of Chlamydia pneumoniae in the pathogenesis of atherosclerosis has so far mainly been investigated in patients suffering from coronary heart disease; the other vascular regions have virtually been ignored. The aim of this study was to carry out a statistical survey of serological markers of a C. pneumoniae infection in patients with different patterns of atherosclerosis manifestation. PATIENTS AND METHODS: 340 patients were examined for the atherosclerotic alteration of peripheral arteries of the lower limbs, carotid arteries and coronary arteries by ultrasound scan and/or angiography. Immunoglobulin(Ig)G and IgA-rELISA were used to measure chlamydial lipopolysaccharide antibodies. Species determination was performed using the IgG micro-immunofluorescence test.
RESULTS: 24.0% of atherosclerotic cases (A) and 52.3% of controls (C) were negative for C. pneumoniae lipopolysaccharide antibodies (p = 0.00002). By contrast, 45.1% of atherosclerotic cases and 16.9% of controls were positive for both IgG and IgA (p = 0.00002). The mean antibody titers of the atherosclerosis group were higher than in the control group (IgG positive xAIgG = 344, xCIgG = 272; IgG and IgA positive xAIgG = 576, xCIgG = 486 and xAIgA = 120, xCIgA = 91). Concerning atherosclerosis manifestation in various vascular regions, no significant differences were found between IgG and IgA antibody titers and prevalence.
CONCLUSIONS: The results show that a persistent C, pneumoniae infection with evidence of lipopolysaccharide immunoglobulin G and A is equally associated with the atherosclerotic alteration of coronary arteries, carotid arteries and peripheral arterial occlusive disease, irrespective of the severity of atherosclerosis and with no predisposition to any particular vascular region.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10611843     DOI: 10.1024/0301-1526.28.4.259

Source DB:  PubMed          Journal:  Vasa        ISSN: 0301-1526            Impact factor:   1.961


  5 in total

1.  Chlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individuals.

Authors:  A Schumacher; A B Lerkerød; I Seljeflot; L Sommervoll; I Holme; J E Otterstad; H Arnesen
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

Review 2.  Role of Helicobacter pylori infection in pathogenesis of atherosclerosis.

Authors:  Rajesh Vijayvergiya; Ramalingam Vadivelu
Journal:  World J Cardiol       Date:  2015-03-26

3.  Antibodies to 60-kilodalton heat shock protein and outer membrane protein 2 of Chlamydia pneumoniae in patients with coronary heart disease.

Authors:  Alessandra Ciervo; Paolo Visca; Andrea Petrucca; Luigi Maria Biasucci; Attilio Maseri; Antonio Cassone
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

4.  T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions.

Authors:  Marisa Benagiano; Annalisa Azzurri; Alessandra Ciervo; Amedeo Amedei; Carlo Tamburini; Mauro Ferrari; John L Telford; Cosima T Baldari; Sergio Romagnani; Antonio Cassone; Mario M D'Elios; Gianfranco Del Prete
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-09       Impact factor: 11.205

5.  Chlamydophila pneumoniae infection and cardiovascular disease.

Authors:  Rajnish Joshi; Bidita Khandelwal; Deepti Joshi; Om Prakash Gupta
Journal:  N Am J Med Sci       Date:  2013-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.